MoonLake's Sonelokimab Hits All Endpoints in Phase 3 IZAR-1 Psoriatic Arthritis Trial

MoonLake Immunotherapeutics (NASDAQ: MLTX) announced positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis. The trial met all clinical endpoints at Week 16, marking the second major Phase 3 win for the IL-17A/F Nanobody after the hidradenitis suppurativa VELA program. MLTX closed at $18.26 on Friday.

Sonelokimab 60 mg with induction achieved a 42.1% ACR50 response on the primary endpoint at Week 16. Across key secondary endpoints, 66.5% of patients reached ACR20, 41.2% achieved Minimal Disease Activity, and 61% of patients with skin involvement hit PASI90. Patient-reported outcomes showed clinically meaningful improvement: mean HAQ-DI change was -0.427 and SF-36 Physical Component Summary score was 6.54.

The trial remains blinded; no placebo comparison data were disclosed, consistent with FDA-agreed unblinding protocol. The blinded safety analysis showed a profile consistent with prior sonelokimab studies, with no new safety signals and low dropout through Week 16.

IZAR-1 is the first of two registrational trials in the IZAR program. IZAR-2 enrolls TNF-inhibitor-refractory patients and includes a risankizumab (AbbVie’s Skyrizi) active comparator arm. Enrollment is expected to complete in Q3 2026, with topline data expected in H1 2027.

The readout matters because it validates sonelokimab outside of HS, where MoonLake already plans a BLA submission in the second half of 2026. The IL-17A/F dual inhibition mechanism, which blocks IL-17A/A, IL-17A/F, and IL-17F/F dimers, differentiates sonelokimab from Novartis’ Cosentyx (IL-17A only) and AbbVie’s Skyrizi (IL-23). The IZAR-1 data position the drug to compete in a psoriatic arthritis market worth upward of $10 billion annually.

MoonLake reported $537 million in cash as of June 30 and expects runway to mid-2028, with up to $400 million in additional non-dilutive debt available from Hercules Capital. The IZAR-1 results land ahead of a catalyst-heavy second half: HS BLA submission, IZAR-2 enrollment completion, and the Phase 2 P-OLARIS imaging trial in PsA and axial spondyloarthritis.

The PsA indication opens a second major market for MoonLake, with approximately 30% of psoriasis patients developing psoriatic arthritis. The absolute ACR50 response (42.1%) is consistent with what other IL-17 programs have shown in bio-naïve populations, though cross-trial comparisons are limited without placebo-adjusted data. The multi-domain efficacy across joint, skin, function, and patient-reported outcomes supports the broad mechanism thesis MoonLake has advanced since its Phase 2 ARGO trial.

Read the full press release on MoonLake’s investor site.

What It Means for the Trade

The first thing a trader should do with IZAR-1 is discount the headline correctly. The 42.1% ACR50 is an absolute response in a blinded readout with no placebo arm disclosed — the FDA-agreed design releases topline without the placebo comparison, so the number that looks like a blockbuster result is roughly in line with what Cosentyx, Skyrizi, and Tremfya-class drugs show in bio-naïve PsA (ACR50 in the 30-45% range with placebo adjustments around 20 points). The market’s job over the next few months is to infer the placebo delta from IZAR-2’s active-comparator design. If sonelokimab’s bio-naïve efficacy is merely class-standard, the bull case rests entirely on differentiation — the IL-17A/F dual mechanism and the Nanobody format.

And the differentiation is real, just specific: blocking IL-17F in addition to IL-17A is the same thesis that took Bimzelx (ustekinumab-free, IL-17A/F from UCB) to best-in-class skin clearance in psoriasis. In PsA specifically, IL-17F is implicated in enthesitis and the entheseal inflammation that IL-17A-only agents address partially — if sonelokimab shows differentiated enthesitis/dactylitis data at the congress presentation, that’s the slide that matters, because those domains are where Cosentyx is beatable.

The catalyst calendar is the trade. Sequence: HS BLA submission (H2 2026, imminent), IZAR-2 completion (Q3 2026) and readout (H1 2027) with the Skyrizi head-to-head comparator, and P-OLARIS imaging data. Each is a discrete re-rating event for a company with a clean balance sheet ($537 million cash to mid-2028, plus $400 million Hercules debt capacity) and no dilution overhang. The risk-reward setup — mid-cap, multiple near-term binary events, no imminent cash need — is exactly the profile event-driven biotech accounts hunt.

The endgame question hanging over all of it: MoonLake, at a ~$3-4 billion market cap, becomes an acquisition target the moment it proves a second indication. AbbVie, Novartis, and UCB all have commercial rheumatology/dermatology infrastructure where sonelokimab slots in as a lifecycle asset. A positive IZAR-2 against Skyrizi is the event that would put MoonLake formally in play.

Mechanism and Market Context

Worth understanding what a Nanobody buys you, because it’s more than branding. Sonelokimab is a ~40 kDa single-domain antibody format (versus ~150 kDa for conventional IgG) with an anti-albumin domain for half-life extension. Smaller size means better tissue penetration into inflamed synovium and skin, and the format natively binds IL-17A/F heterodimers — the dominant circulating form of IL-17F-containing activity — which monovalent IL-17A antibodies miss. That’s the mechanistic pitch for beating Cosentyx-class agents: the disease-relevant cytokine isn’t free IL-17A alone.

The PsA market math: roughly $10 billion-plus annually, split between TNF inhibitors (Humira biosimilars collapsing pricing there), IL-17/IL-23/IL-12-23 biologics, and JAK inhibitors (safety-capped). Skyrizi is currently the momentum asset — its convenience (quarterly dosing) and clean efficacy keep taking share — which is exactly why MoonLake put it in IZAR-2 as the comparator. Beating or matching Skyrizi on efficacy with a differentiating enthesitis/safety profile is the only credible path to front-line adoption; matching Cosentyx is not enough in 2026.

Risks and What Could Go Wrong

Ranked: (1) The blinded-design ambiguity cuts both ways. Without placebo data, the market can’t yet verify effect size — and the FDA-agreed unblinding protocol means full clarity may wait for the congress presentation or IZAR-2. A placebo-adjusted ACR50 delta materially below the IL-17 class norm would gut the launch thesis. (2) IZAR-2 is the harder trial. TNF-refractory patients respond less across the class, and the Skyrizi active comparator makes a “win” a high bar — a messy or losing readout in H1 2027 takes the second indication off the table and leaves MoonLake a single-indication HS company. (3) Commercial asymmetry versus incumbents. Even with approvals, MoonLake would launch PsA against AbbVie/Novartis/UCB sales forces with no commercial infrastructure of its own — the realistic value-maximizing path is acquisition, and a delayed IZAR-2 delays that too. (4) HS launch execution. The first BLA decision (acceptance, review timeline, label breadth) arrives before any PsA filing and sets the cash-burn tone. (5) IL-17A/F competition. Bimzelx’s momentum in psoriasis means MoonLake isn’t alone in the dual-inhibition lane; UCB has PsA data of its own and a running commercial head start.

Sizing discipline: the stock at $18.26 with positive HS and PsA Phase 3 topline already reflects meaningful de-risking. The incremental upside needs IZAR-2 or the HS filing to clear — until then, this is a hold-the-event, not a chase-the-headline.